Andrea Necchi, MD

Articles by Andrea Necchi, MD

Tar-200 Plus Anti–PD-1 Therapy Shows Promising Neoadjuvant Activity in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

ByAndrea Necchi, MD,Aislinn Antrim, Managing Editor

October 19th 2025

Andrea Necchi, MD, shared SunRISe-4 primary results demonstrating higher pathologic response and relapse-free survival rates with TAR-200 plus sacituzumab compared with checkpoint inhibitor monotherapy, with no new safety signals observed.

Latest Updated Articles

Andrea Necchi, MD

Articles by Andrea Necchi, MD

Tar-200 Plus Anti–PD-1 Therapy Shows Promising Neoadjuvant Activity in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Latest Updated Articles

Trending on Pharmacy Times

Addressing Drug Resistance in Lung Cancer

Final EMBARK Data Show “Almost Unprecedented” Reduction in Risk of Death With Enzalutamide Plus ADT in Biochemically Recurrent Prostate Cancer

From Mutation to Medicine: Targeted Therapies in Lung Cancer

Tar-200 Plus Anti–PD-1 Therapy Shows Promising Neoadjuvant Activity in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Five-Year NATALEE Data Show Ribociclib Improves Outcomes in High-Risk HR+/HER2– Early Breast Cancer